Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease
- 12 September 2019
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 157 (6) , 1448-1456.e1
Abstract
No abstract availableFunding Information
- U.S. Food and Drug Administration
- University of California, San Diego
- School of Medicine, Johns Hopkins University
- U.S. Food and Drug Administration
- Columbia University
- Bristol-Myers Squibb
- Bristol-Myers Squibb
- U.S. Food and Drug Administration
- Research and Development
- U.S. Food and Drug Administration
- National Institutes of Health
- European Medicines Agency
- Virginia Commonwealth University
This publication has 55 references indexed in Scilit:
- Hepatic steatosis and severity‐related factors in obese childrenJournal of Gastroenterology and Hepatology, 2013
- Increasing Prevalence of Nonalcoholic Fatty Liver Disease Among United States Adolescents, 1988-1994 to 2007-2010The Journal of Pediatrics, 2013
- Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohortJournal of Hepatology, 2012
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsJAMA, 2011
- SAFETY Study: Alanine Aminotransferase Cutoff Values Are Set Too High for Reliable Detection of Pediatric Chronic Liver DiseaseGastroenterology, 2010
- The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 yearsGut, 2009
- Clinical Correlates of Histopathology in Pediatric Nonalcoholic SteatohepatitisGastroenterology, 2008
- Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical TrialsClinical Gastroenterology and Hepatology, 2008
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot studyThe Journal of Pediatrics, 2000